<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952273</url>
  </required_header>
  <id_info>
    <org_study_id>Sort Out XI</org_study_id>
    <nct_id>NCT03952273</nct_id>
  </id_info>
  <brief_title>Sort Out XI - Combo Stent Versus BioMatrix Alpha Stent</brief_title>
  <acronym>SORTOUTXI</acronym>
  <official_title>Randomized Clinical Comparison of the Combined Sirolimus Eluting and Endothelial Progenitor Cell Combo™ Stent and the Biolimus Eluting Absorbable Polymer Coated BioMatrix Alpha™ Stent in Patients Treated With Percutaneous Coronary Intervention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phillip Freeman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OrbusNeich</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biosensors International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      SORT OUT XI Comparison of Combo™ stent and BioMatrix Alpha™ stent in the treatment of
      unselected patients with ischemic heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical comparison of the Sirolimus eluting and endothelial progenitor cell
      Combo™ stent and the Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent in
      patients treated with percutaneous coronary intervention
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device-related Target Lesion Failure (TLF) The composite of cardiac death, target-vessel myocardial infarction (MI), or ischemia-driven target-lesion revascularization</measure>
    <time_frame>Within 12 months</time_frame>
    <description>The primary endpoint will be analyzed using the Kaplan-Meier method. Hazard ratios between groups will be calculated using a Cox proportional hazard model and the primary endpoint in the two per protocol treated groups will be compared with an upper one-sided 95% confidence interval. Patients treated with the ComboTM stent will be used as the reference group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target Lesion Revascularisation (TLR)</measure>
    <time_frame>Within 12 months</time_frame>
    <description>Repeat/new revascularization (PCI or CABG) within the stent or within a 5-mm border proximal or distal to the stent. (Angina, CCS &gt; 1 related to the index lesion/vessel and diameter stenosis ≥ 50%. Diameter stenosis will be assessed by eyeballing, FFR &lt;0.80, or iFR&lt; 0.90). TLR will be clinically driven.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual components of the primary end point comprise the secondary end points</measure>
    <time_frame>Clinical follow-up will be continued through 5 years</time_frame>
    <description>cardiac death; MI; clinically indicated TLR; all death (cardiac and noncardiac) and target vessel revascularisation (TVR); definite, probable, possible, and overall stent thrombosis according to the Academic Research Consortium definition (22); and a patient-related composite end point (all death, all MI (including procedure related MI), or any revascularization). For continuous variables, the difference between the treatment groups will be evaluated using Wilcoxon's rank-sum test. For discrete variables, the differences will be given as numbers and in percentages and will be analyzed using Fisher's exact test. Two-sided test will be used, and a pvalue of 0.05 considered significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Cardiac Death</measure>
    <time_frame>Through 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Myocardial Infarction</measure>
    <time_frame>Through 5 years</time_frame>
    <description>The acute MI diagnosis follows &quot;The Joint ESC/ACCF/AHA/WHF Task Force on &quot;Third Universal Definition of MI&quot; (23), which has been adapted by Academy Research Consortium (22).
In cases of updates of the definition of MI, the latest definition will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization due to clincal symptoms</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Angina, CCS &gt; 1 related to the index lesion/vessel and diameter stenosis ≥ 50%. Diameter stenosis will be assessed by eyeballing, FFR &lt;0.80, or iFR&lt; 0.90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with all cause mortality</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Cardiac and non-cardiac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization due to clincal symptoms</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Angina, CCS &gt; 1 related to the index lesion/vessel and diameter stenosis ≥ 50%. Diameter stenosis will be assessed by eyeballing, FFR &lt;0.80, or iFR&lt; 0.90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with stent thrombosis</measure>
    <time_frame>Through 5 years</time_frame>
    <description>Definite, probable, possible and overall according to the Academic Research Consortium definition (22)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Patient-related composite end point</measure>
    <time_frame>Through 5 years</time_frame>
    <description>All death, all MI (including procedure related MI) or any revascularisation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3140</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Combo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCI with COMBO stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BioMatrix Alpha</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCI with BioMatrix Alpha stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PCI with BioMatrix Alpha™ stent</intervention_name>
    <description>Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent</description>
    <arm_group_label>BioMatrix Alpha</arm_group_label>
    <other_name>Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PCI with Combo™ stent</intervention_name>
    <description>Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent</description>
    <arm_group_label>Combo</arm_group_label>
    <other_name>Combined sirolimus eluting and endothelial progenitor cell Combo™ stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting
        coronary stents at one of the three heart centers in Aarhus, Odense and Aalborg can be
        included in the study.

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  The patient does not wish to participate

          -  The patient is not able to consent to randomization (eg. intubated patients)

          -  The patient do not speak Danish

          -  The patient is already included in the SORT OUT XI study

          -  Life expectancy &lt;1 year

          -  Allergic to study related treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Freemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phillip Freemann, MD</last_name>
    <phone>+4597664457</phone>
    <email>p.freeman@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leif Thuesen, MD</last_name>
    <phone>+4597664465</phone>
    <email>leif.thuesen@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evald H Christiansen, MD</last_name>
      <email>evald.christiansen@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense Unversity Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisette O Jensen, MD</last_name>
      <email>okkels@dadlnet.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Phillip Freeman</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <keyword>Drug eluting stent</keyword>
  <keyword>Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only shared with collaborators</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

